A Randomized Trial Comparing Initial Haart Regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in Combination with Two Nucleoside Reverse Transcriptase Inhibitors
- 1 August 2003
- journal article
- clinical trial
- Published by SAGE Publications in Antiviral Therapy
- Vol. 8 (6) , 595-602
Abstract
Background: A triple-class HAART regimen may be associated with a better virological effect than conventional regimens, but may also lead to toxicity and more profound resistance. Methods: Randomized, controlled, open-label trial of 233 protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-naive HIV-infected patients allocated to a regimen of nelfinavir and nevirapine (1250/200 mg twice daily; n=118) or ritonavir and saquinavir (400/400 mg twice daily; n=115), both in combination with two nucleoside reverse transcriptase inhibitors. The primary end-point was HIV RNA ≤20 copies/ml after 48 weeks (missing value=failure). Patients remained under follow-up also in case of switch from the randomized therapy. Results: At baseline, the median CD4 cell counts were 126 (range: 0–942) (nelfinavir/nevirapine) and 150 (0–642) (ritonavir/saquinavir) cells/mm 3 , and HIV RNA measurements 5.0 copies/ml (1.3–6.4) in both groups. A total of 102 (86%) and 101 (88%) were antiretroviral-naive. Within 48 weeks, 35 and 44% discontinued randomized therapy; P=0.13. Of these, 80 and 73% switched therapy due to adverse events; P=0.99. At week 48, 69 and 56%, respectively, had a HIV RNA ≤20 copies/ml; P=0.037. Conclusion: A regimen of nelfinavir/nevirapine had a favourable virological effect and tolerability over a 48-week period compared with ritonavir/saquinavir, when administered in combination with two nucleoside reverse transcriptase inhibitors. However, more extensive follow-up is required to determine the long-term consequences of triple class HAART regimens, including the development of broad drug resistance.Keywords
This publication has 26 references indexed in Scilit:
- Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosineAIDS, 2003
- Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 TrialThe Journal of Infectious Diseases, 2003
- Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS, 2003
- Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or NevirapineHIV Research & Clinical Practice, 2003
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapyHIV Medicine, 2001
- Comparison of P-Triglyceride Levels among Patients with Human Immunodeficiency Virus on Randomized Treatment with Ritonavir, Indinavir or Ritonavir/SaquinavirScandinavian Journal of Infectious Diseases, 2001
- The Danish Protease Inhibitor Study: A Randomized Study Comparing the Virological Efficacy of 3 Protease Inhibitor–Containing Regimens for the Treatment of Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 2000
- AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patientsAIDS, 2000
- Time of initiation of antiretroviral therapy: impact on HIV-1 viraemiaAIDS, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999